

SoonerCare Fax Blast

December 4, 2012

Subject: Pharmacy Update

Topical Antifungal Medications Step Therapy

The following changes will take effect December 17, 2012.

Tier 1 products are available without prior authorization. OTC products require a prescription, and should be billed using the prescriber's NPI.

Tier 2 Authorization Criteria:

- 1) Documented trials of at least two Tier-1 topical antifungal products within the last 30 days
- 2) For treatment of onychomycosis, a trial of oral antifungals (6 weeks for fingernails and 12 weeks for toenails) is required prior to approval of Penlac®

Tier-1	Tier-2
ciclopirox-0.77% cream	ciclopirox solution, shampoo, & gel (Penlac® and
	Loprox®), & 0.77% Susp
lotrimazole cream, solution	miconazole/zinc oxide/white petrolatum (Vusion®)
econazole 1% cream	oxiconazole (Oxistat [®])
ketoconazole 2% cream, shampoo	sertaconazole nitrate (Ertaczo®)
nystatin cream, ointment	butenafine (Mentax®)
clotrimazole 1% cream (OTC)*	ketoconazole gel (Xolegel™)
terbinafine 1% cream (OTC)*	naftifine (Naftin®)
tolnaftate 1% cream (OTC)*	sulconazole (Exelderm [®])
	ketoconazole foam 2% (Extina®)
	nystatin/triamcinolone- cream, ointment
	clotrimazole/betamethasone-1% & 0.05% cream, lotion

^{*}OTC products are covered for members age 0-20 years. For members age 21 and older, please use other Tier-1 products.

Changes to Drug Coverage for Dual Eligible Medicare Members

Effective January 1, 2013, Medicare Part D prescription drug plans will cover benzodiazepines, and will also cover barbiturates used in the treatment of epilepsy, cancer, or a chronic mental disorder. SoonerCare will no longer cover these medications for members who are eligible for Medicare. The exception to this change is butalbital, which will continue to be covered for headache or pain diagnoses. For a list of products covered by SoonerCare for dual eligible members, please see www.okhca.org/providers/rx.

PA Criteria: www.okhca.org/providers/rx/pa PA forms: www.okhca.org/rx-forms